Diclofenac Sodium gel, 1% + Voltaren® Gel + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis
Conditions
Osteoarthritis
Trial Timeline
Aug 1, 2015 → Mar 1, 2016
NCT ID
NCT02596451About Diclofenac Sodium gel, 1% + Voltaren® Gel + Placebo
Diclofenac Sodium gel, 1% + Voltaren® Gel + Placebo is a phase 3 stage product being developed by Glenmark Pharmaceuticals for Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02596451. Target conditions include Osteoarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02596451 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoarthritis
Other Products from Glenmark Pharmaceuticals
Nitric OxidePhase 3
77
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerPhase 3
77
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)Phase 3
77
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboPhase 3
77
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% + PlaceboPhase 3
77